Direct Oral Anticoagulants vs. Heparin for Cancer-Related Stroke
Author Information
Author(s): Essibayi Muhammed Amir MD, Azzam Ahmed Y. MD, MEng, Sener Ugur MD, Altschul David MD, Atik Merve MD, Keser Zafer MD
Primary Institution: Mayo Clinic, Rochester, MN, USA
Hypothesis
What is the efficacy and safety of direct oral anticoagulants compared to heparin products for stroke prevention in cancer patients?
Conclusion
DOACs may have a similar efficacy and safety profile to heparin products for preventing recurrent stroke in cancer patients.
Supporting Evidence
- DOACs showed lower rates of intracerebral hemorrhage compared to heparin.
- Mortality rates were significantly lower in patients treated with DOACs than those treated with heparin.
- Overall hemorrhagic complications were lower in the DOAC group.
- Rates of recurrent ischemic stroke or TIA were similar between the two treatment groups.
Takeaway
This study looked at how two types of blood thinners work for people with cancer who have had a stroke. It found that one type, called DOACs, might be just as good as the other type, heparin.
Methodology
A systematic review and meta-analysis were conducted using PubMed to evaluate studies on antithrombotics for cancer-associated stroke.
Potential Biases
There is a risk of selection bias due to the varying definitions of active cancer and the retrospective design of most studies.
Limitations
The study is limited by the retrospective nature of included studies and the small number of studies available.
Participant Demographics
The study included 439 patients treated with DOACs, with a mean age of 69, and 3968 patients treated with heparin, with a mean age of 67.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 0%–53.7%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website